IV Iron Expert Exchange: Data-driven Debates on the Revolutionary Role of IV Iron in Heart Failure
To register in advance click here: https://us06web.zoom.us/webinar/register/WN_lNOW5KvGQcy37LkauNu7fg
This timely and dynamic educational activity is targeted to cardiologists and key members of their interprofessional and multidisciplinary care teams who manage patients with heart failure. In this Expert Exchange-based format—an educational modality that incorporates elements of a traditional Oxford-style debate, and provides enhanced audience interactivity, a broader platform to embrace diverse and evolving clinical perspectives, and a flexible framework within which to incorporate emerging science and breaking data—activity attendees will be immersed in a lively and dynamic discussion between key thought leaders in the world of heart failure (HF).This session will set the stage with a foundational circumscription of iron deficiency (ID) pathophysiology and clinical gravity in HF, particularly in heart failure with reduced ejection fraction (HFrEF), as well as the impact of elevated hepcidin on iron supplementation strategies. The case-based Expert Exchange will follow and will include an exploration of clinical trial data for intravenous (IV) iron therapies in HF and recently-updated expert consensus HF management guidelines, with emphasis on the emerging role of IV iron on improved clinical endpoints in HFrEF. Key teaching points up for data-driven debate include the safety and efficacy profiles of next-generation IV iron products, the importance of total dose infusions (TDIs), the practical utility of digitalized checklists to ensure adherence to guideline-directed medical therapy (GDMT) in HF, and a comparative analysis of the labeled indications and approved dosing regimens of currently-available IV iron products.
Cardiologists and key members of their interprofessional and multidisciplinary teams who manage patients with heart failure.
- Discuss the fundamental principles of iron metabolism and absorption, with a focus on how these principles apply to treatment of iron deficiency (ID) in heart failure (HF), and identify key distinctions between HFrEF and HFpEF.
- Recognize the robust impact of comorbid ID and HF, with or without concomitant anemia, and describe the prognostic implications of ID on patient functional capacity, quality of life, and HF morbidity and mortality outcomes.
- Evaluate the essential utility of serum ferritin and transferrin saturation (TSAT) as ID diagnostic laboratory indices in HF, and as foundational clinical parameters for guiding treatment with intravenous (IV) iron.
- Appraise completed, ongoing, and planned clinical trials of IV iron therapies for ID in HF, and identify pivotal data readouts that have influenced current practice and consensus HF guideline statements (2021 ESC and 2022 ACC/AHA/HFSA).
- Understand how the innovative nanoparticle design of next-generation IV iron products improves upon the safety profiles of earlier generation products, with anaphylaxis rates as low as 0.1%.
- Using a case-based format, analyze how proinflammatory cytokines and elevated hepcidin levels impact the comparative clinical utility of oral vs IV iron supplementation modalities in HFrEF.
Presented by Creative Educational Concepts, LLC.
Supported through an independent educational grant from American Regent.
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP
The Mary and Gordon Cain Chair and Professor of Medicine
Associate Provost of Faculty Affairs
Senior Associate Dean of Faculty Development
Director, Winters Center for Heart Failure Research
Assoc. Director, Cardiovascular Research Institute
Vice-Chair of Medicine, Baylor College of Medicine
Medicine Chief, DeBakey VA Medical Center
Robert J. Mentz, MD
Chief, Heart Failure Section
Duke University Medical Center
Muthiah Vaduganathan, MD, MPH
Co-Director, Center for Cardiometabolic Implementation Science
Harvard Medical School
Brigham and Women’s Hospital
It is the policy of Creative Educational Concepts, LLC, (CEC) to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CME/CE activities. Activity planners, faculty, peer reviewers, and CEC staff must disclose to the participants any relationships with ineligible entities whose products or devices may be mentioned in this CE activity, or with the commercial supporter of this CE activity. An ineligible entity is defined as any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Financial relationships may include research grants, consultant fees, travel, advisory boards, consultancy, speakers’ bureaus, other benefits, or having a self-managed equity interest in a company.
CEC has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Muthiah Vaduganathan, MD, MPH–disclosures to come.
Biykem Bozkurt, MD, PhD, FHFSA, FACC, FAHA, FACP–disclosures to come.
Robert J. Mentz, MD–has disclosed that he receives grants from American Regent, AstraZeneca, Boston Scientific, Cytokinetics, Medtronic, Merck, and Novartis. He receives research support from American Regent, AstraZeneca, Boston Scientific, Cytokinetics, Medtronic, Merck, and Novartis. He is an advisor or consultant to BI/Lilly, Bayer, Cytokinetics, Merck, Novartis, Pharmacosmos, Respicardia, Roche, Sanofi, and Vifor.
Information to come
Bryan C. Taylor, PharmD–has no relevant financial relationships to disclose in relation to the content of this activity.
Ashley C. Lilly, MHA–has no relevant financial relationships to disclose in relation to the content of this activity.
Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CEC, the faculty, and any commercial supporter of this activity do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.
In support of improving patient care, Creative Educational Concepts is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 1.5 hour of Interprofessional Continuing Education (IPCE) credit for learning and change.
CEC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This application-based activity is approved for 1.0 contact hour (.15 CEUs) of continuing pharmacy education credit (JA0007101-0000-22-018-L01-P)
This activity is designated for 1.5 contact hours.
Upon completion of a CE request form, statements of credit for physicians, physician assistants, and nurses will be issued within 30 business days. Pharmacy credit will be reported directly to the National Association of Boards of Pharmacy® (NABP®) CPE Monitor electronic CE tracking system.
- 1.50 ACPE Pharmacy
- 1.50 AMA PRA Category 1 Credit™
- 1.50 ANCC
- 1.50 ICPE
- 1.50 Participation